RESUMO
Objective: To evaluate the efficacy and safety of qiliqiangxin capsule in treating the patients with chronic heart failure (CHF). Methods: We searched the databases of Pubmed, EMBASE, Web of science, Wanfang, VIP, CBM and CNKI from 2007-01 to 2017-03 to collect the randomized trials of qiliqiangxin capsule in treating CHF patients. Blood levels of NT-proBNP, 6 minutes walkingdistance (6MWD), left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD) and Minnesota living with heart failure questionnaire (MLHFQ) scores were compared between qiliqiangxin capsule treated patients and control patients. Results: A total of 22 randomized trials were finally enrolled which included 1988 patients by 2 groups: Qiliqiangxin capsule group, n=1002 and Control group, n=986. Patients were followed-up at the mean 6.5 months. Compared with Control group, Qiliqiangxin capsule group had decreased blood level of NT-proBNP, weighted mean difference (WMD)= -194.97, 95％ CI (-287.95 to -101.99), increased LVEF, WMD=5.24, 95％ CI (3.38-7.11), reduced LVEDD, WMD= -0.94, 95％ CI (-1.46 to -0.43), elevated 6MWD, WMD=53.81, 95％ CI (46.9-60.73), lower MLHFQ score WMD= -8.11, 95％ CI(-10.23 to -6.0) and less adverse events occurrence, OR=0.44, 95％ CI (0.25-0.79),P<0.01. Conclusion: Qiliqiangxin capsule was safe and effective for improving the cardiac function and quality of life in CHF patients.